Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
7
×
boston blog main
clinical trials
7
×
life sciences
national blog main
boston top stories
fda
deals
national top stories
rare disease drugs
san francisco blog main
alexion pharmaceuticals
dyne therapeutics
investing
myotonic dystrophy type 1
roche
san diego blog main
akouos
ally bridge group
alnylam pharmaceuticals
amyotrophic lateral sclerosis (als)
astellas pharma
astellas pharmaceuticals
atlas venture
audentes therapeutics
autoimmune disorders
avapritinib
avidity biosciences
big data analytics
biotech ipos
blackrock
bluebird bio
blueprint medicines
boehringer ingelheim
california institute for biomedical research
casdin capital
complement system
cstone pharmaceuticals
decibel therapeutics
What
drug
7
×
medicines
7
×
ipo
genetic
muscle
therapeutics
candidate
company
developing
disease
diseases
dyne
fda
lead
million
pharma
pharmaceuticals
raised
rare
roche
team
affects
ago
alternative
americans
analysis
approval
approved
autoimmune
bio
biotech
biotechs
blueprint
bring
brings
cancer
caught
causing
considering
currently
Language
unset
Current search:
medicines
×
drug
×
boston
×
" clinical trials "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds